

10th June 2010

Plethora Solutions Holdings plc
("Plethora" or "the Company")

LTIP Awards

Plethora Solutions Holdings plc (AIM: PLE), the UK-based specialty pharmaceutical company, announces that following the adoption of the new long term incentive plan ("LTIP") approved by shareholders at the General Meeting on 7 December 2009 the Company has made the following awards to directors.

Dr Steven Powell	578,000 shares
Dr Mike Wyllie	533,000 shares
Bill Robinson	125,500 shares
Ronald Openshaw	245,500 shares

These awards were made with a grant date of 8 June 2010 and a maturity date of 8 June 2013. The awards will only vest to the extent that the individual remains an employee or director of the Company throughout that period and are subject to the achievement of performance criteria linked to the Company's objectives during that period.

-Ends-

Enquiries:

Plethora Solutions

Steven Powell/Ronald Openshaw

FinnCap

Geoff Nash/Marc Young

Hansard Communications

Kirsty Corcoran/John Bick

Tel : +44(0) 20 3077 5400

Tel : +44(0) 20 7600 1658

Tel: +44(0) 20 7245 1100

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503), interstitial cystitis (PSD597), gynaecological pain (PSD508), erectile dysfunction (PSD510) and premature ejaculation (PSD502). Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of therapeutic products for the treatment of urology, andrology and obstetric conditions. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L).

Further information is available at www.plethorasolutions.co.uk.

